XJPX6190
Market cap7mUSD
Dec 24, Last price
326.00JPY
1D
-1.21%
1Q
-28.51%
Jan 2017
-82.84%
IPO
-87.60%
Name
PhoenixBio Co Ltd
Chart & Performance
P/E
44.91
P/S
0.69
EPS
7.26
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
6.85%
Revenues
1.72b
-19.24%
Net income
26m
-94.65%
CFO
-79m
L
Profile
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 1,715,321 -19.24% | 2,124,051 60.33% | 1,324,817 30.71% | ||
Cost of revenue | 1,675,051 | 876,676 | 897,140 | ||
Unusual Expense (Income) | |||||
NOPBT | 40,270 | 1,247,375 | 427,677 | ||
NOPBT Margin | 2.35% | 58.73% | 32.28% | ||
Operating Taxes | 33,407 | 17,314 | (5,031) | ||
Tax Rate | 82.96% | 1.39% | |||
NOPAT | 6,863 | 1,230,061 | 432,708 | ||
Net income | 26,378 -94.65% | 493,329 -227.16% | (387,970) 63.01% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 37,797 | 142,931 | |||
BB yield | -2.07% | -6.84% | |||
| Debt | |||||
Debt current | 231,588 | 915,257 | 30,995 | ||
Long-term debt | 735,280 | 469,683 | 1,146,847 | ||
Deferred revenue | |||||
Other long-term liabilities | 3,343 | 3,339 | 5,621 | ||
Net debt | (427,514) | (296,463) | (158,665) | ||
| Cash flow | |||||
Cash from operating activities | (79,307) | 277,491 | 16,398 | ||
CAPEX | (38,773) | (12,368) | (6,771) | ||
Cash from investing activities | 115,358 | (156,340) | (6,975) | ||
Cash from financing activities | (244,879) | 86,630 | (34,658) | ||
FCF | (192,904) | 856,311 | 705,276 | ||
| Balance | |||||
Cash | 1,385,107 | 1,555,323 | 1,325,507 | ||
Long term investments | 9,275 | 126,080 | 11,000 | ||
Excess cash | 1,308,616 | 1,575,200 | 1,270,266 | ||
Stockholders' equity | 1,014,942 | 843,462 | 260,195 | ||
Invested Capital | 1,508,947 | 1,741,287 | 1,599,804 | ||
ROIC | 0.42% | 73.63% | 27.28% | ||
ROCE | 1.59% | 48.26% | 22.99% | ||
| EV | |||||
Common stock shares outstanding | 3,782 | 3,397 | 3,302 | ||
Price | 482.00 -21.63% | 615.00 17.37% | 524.00 -14.94% | ||
Market cap | 1,822,808 -12.75% | 2,089,082 20.74% | 1,730,217 -13.14% | ||
EV | 1,395,294 | 1,794,619 | 1,586,552 | ||
EBITDA | 65,495 | 1,271,075 | 513,915 | ||
EV/EBITDA | 21.30 | 1.41 | 3.09 | ||
Interest | 2,927 | 3,072 | 952 | ||
Interest/NOPBT | 7.27% | 0.25% | 0.22% | ||